US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 2.70 against a street estimate of 1.80 — a beat of 50.0%.
Analysts rate ANI Pharmaceuticals Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $105.78.
MIXED ANI reported strong Q2 growth driven by Cortrophin (up 43% YoY to $117.1M), modest Cortrophin guidance cut for FY26, and early positive traction from new gout sales force expansion launched late Q2. Q2 2026 Call did not discuss geographic segments. Analysts pressed management on guidance revision disconnect (guidance cut despite Q2 beat), payer mix differences in gout vs. base, and M&A appetite. Management deflected on specifics (gout flares, prescriber penetration, G2N pressure) citing competitive sensitivity but reiterated strong leading indicators and H2 confidence without quantifying patient-level dynamics. 2026-08-07…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.88% |
| Soleus Capital Management, L.P. | 3.78% |
| Vanguard Capital Management, LLC | 3.65% |
| State Street Corp | 3.62% |
| TANG CAPITAL MANAGEMENT LLC | 3.08% |
| Dimensional Fund Advisors, Inc. | 2.71% |
| American Century Companies Inc | 2.50% |
| Arrowstreet Capital Limited Partnership | 2.45% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • For the three months ended September 30, 2026, net revenue was $290,777 thousand, up from $227,813 thousand in the same period of | 2026-11-05 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • ANI Pharmaceuticals announced a recommended public cash offer to acquire Egetis Therapeutics AB. • The proposed consideration is | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net revenue was $290.8 million, up 27.6% year over year. • GAAP net income available to common shareholders wa | 2026-11-05 |
| Board / officer change · Q3 2026 ANI PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Filing Date: August 24, 2026 (reporting events from August 19 and August 23, 2026) • | 2026-08-24 |
| Quarterly report · Q2 2026 ANI PHARMACEUTICALS, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Revenues (6M 2026): $503.5 million vs. $408.5 million (6M 2025) — increase o | 2026-08-07 |
| Results announced · Q3 2026 ANI PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Total Net Revenues: $266.0 million – up 25.9% year-over-year • Q2 2026 GAAP | 2026-08-07 |
| Board / officer change · Q2 2026 ANI PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 21, 2026 • 22,750,198 shares of Common Stock outstanding as | 2026-05-21 |
| Reg FD disclosure · Q2 2026 ANI PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics or headline numbers are disclosed in this Form 8-K fil | 2026-05-13 |
Readable in the app.
| Announcement | Date |
|---|---|
| Credit facility arranged to finance recommended cash offer for Egetis Therapeutics ANI Pharmaceuticals announced a recommended cash offer to acquire all outstanding shares, convertible debt and warrants of Sweden-based Egetis Therapeutics. The offer is SEK 11.25 per Egetis | 2026-11-05 |
| Preliminary 2025 results and 2026 financial guidance provided ANI Pharmaceuticals announced preliminary unaudited financial results for Q4 and full year 2025, along with 2026 guidance on January 12, 2026. The company's CEO will present at the J.P. Morg | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ANI Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.